All news

Wall Street Zen cuts Akebia Therapeutics to strong sell

Alpha Vantage · MarketBeat · · AI-summarised by FinFlash

Wall Street Zen downgraded Akebia Therapeutics (NASDAQ:AKBA) from "sell" to "strong sell," even as MarketBeat shows an average analyst rating of "Hold" with a $3.50 price target. The biopharmaceutical stock trades near its 12-month low after meeting EPS estimates but missing revenue forecasts. Institutional investors have made significant changes to their holdings.

Read original source

AKBA company analysis

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.